CIGNA (NYSE:CI) had its target price lifted by equities researchers at Oppenheimer to $237.00 in a research note issued on Friday. The brokerage currently has an “outperform” rating on the health services provider’s stock. Oppenheimer’s price objective indicates a potential upside of 14.58% from the stock’s current price. Oppenheimer also issued estimates for CIGNA’s FY2017 earnings at $10.46 EPS.
Other research analysts also recently issued reports about the company. Jefferies Group boosted their target price on CIGNA from $201.00 to $221.00 and gave the stock a “buy” rating in a research note on Friday, October 13th. Zacks Investment Research upgraded CIGNA from a “hold” rating to a “buy” rating and set a $214.00 target price on the stock in a research note on Monday, October 9th. Citigroup boosted their target price on CIGNA from $198.00 to $231.00 and gave the stock a “buy” rating in a research note on Friday, November 3rd. ValuEngine upgraded CIGNA from a “hold” rating to a “buy” rating in a research note on Sunday, December 31st. Finally, BMO Capital Markets started coverage on CIGNA in a research report on Monday, October 16th. They set a “market perform” rating and a $210.00 price target for the company. Three equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $210.12.
Shares of CIGNA (CI) traded up $1.83 during mid-day trading on Friday, reaching $206.84. The company had a trading volume of 1,076,251 shares, compared to its average volume of 1,384,926. CIGNA has a 1 year low of $141.93 and a 1 year high of $227.13. The company has a current ratio of 0.39, a quick ratio of 0.39 and a debt-to-equity ratio of 0.37. The stock has a market cap of $51,220.00, a P/E ratio of 22.72, a price-to-earnings-growth ratio of 1.37 and a beta of 0.44.
In other news, EVP Alan Muney sold 15,345 shares of the business’s stock in a transaction dated Monday, November 27th. The stock was sold at an average price of $200.80, for a total value of $3,081,276.00. Following the completion of the transaction, the executive vice president now owns 28,457 shares of the company’s stock, valued at approximately $5,714,165.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP John M. Murabito sold 6,099 shares of the business’s stock in a transaction dated Thursday, January 18th. The shares were sold at an average price of $220.10, for a total value of $1,342,389.90. Following the completion of the transaction, the executive vice president now directly owns 68,026 shares of the company’s stock, valued at approximately $14,972,522.60. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 75,655 shares of company stock valued at $15,503,365. 1.30% of the stock is currently owned by insiders.
Several hedge funds have recently modified their holdings of the company. Ameriprise Financial Inc. lifted its holdings in shares of CIGNA by 4.8% in the 3rd quarter. Ameriprise Financial Inc. now owns 3,776,414 shares of the health services provider’s stock valued at $705,889,000 after buying an additional 171,712 shares during the period. Sanders Capital LLC lifted its holdings in shares of CIGNA by 1.8% in the 4th quarter. Sanders Capital LLC now owns 3,015,393 shares of the health services provider’s stock valued at $667,646,000 after buying an additional 52,400 shares during the period. Investec Asset Management LTD lifted its holdings in shares of CIGNA by 35.4% in the 3rd quarter. Investec Asset Management LTD now owns 1,849,598 shares of the health services provider’s stock valued at $345,764,000 after buying an additional 483,904 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of CIGNA by 3.6% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,431,295 shares of the health services provider’s stock valued at $267,567,000 after buying an additional 49,879 shares during the period. Finally, Legal & General Group Plc lifted its holdings in shares of CIGNA by 0.7% in the 3rd quarter. Legal & General Group Plc now owns 1,424,817 shares of the health services provider’s stock valued at $266,335,000 after buying an additional 9,921 shares during the period. 88.07% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: “Oppenheimer Boosts CIGNA (CI) Price Target to $237.00” was first reported by American Banking and Market News and is the sole property of of American Banking and Market News. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/02/02/oppenheimer-boosts-cigna-ci-price-target-to-237-00.html.
CIGNA Company Profile
Cigna Corporation (Cigna), together with its subsidiaries, is a health services company. The Company offers medical, dental, disability, life and accident insurance and related products and services. The Company’s segments include Global Health Care, Global Supplemental Benefits, Group Disability and Life, and Other Operations and Corporate.
